Top 5 drugs with patent expiration in 2019: Roche exclusive 3

Patent expiration is a problem that all successful pharmaceutical companies have to face in the end, and Roche, the Swiss pharmaceutical giant, will face a particularly dangerous year in this regard In 2019, the company has three blockbuster anti-cancer drugs that will face low-cost generic competition in the U.S market According to an article recently published by evaluatepharma, a pharmaceutical market research organization, there will be 5 important products in the U.S market that will lose their market monopoly rights in 2019, among which Roche has 3 monopoly rights, namely Avastin (Avastin, generic name: Bevacizumab), Herceptin (Herceptin, generic name: trastuzumab), Tarceva (troika, generic name: erlotinib) The other two are invega sustenna, an antipsychotic drug of Johnson & Johnson, and orencia, an anti-inflammatory drug of Bristol Myers Squibb However, for Roche, the financial impact may not be as serious as in the past, because of the three drugs, avidin and Herceptin are biological agents, and the market penetration rate of bio generic drugs is difficult to measure In this area, even the launch date is difficult to determine: according to the agreement reached between mylan and Roche, the Hessaitin biosimilars developed by the former will be available around the middle of 2019, while Amgen is the main competitor for the introduction of anverine biosimilars, although court proceedings are still ongoing and hearings are scheduled for later this year and 2020 As a result, this year's listing is not widely expected In contrast, rituxan, another Roche heavyweight product, is expected to be hit hard in 2019 In the United States, the key patent of rituximab in the treatment of blood cancer has expired at the end of 2018 If the market penetration of rituximab bio generic drugs in this market is as rapid as that in Europe, it will be a painful start for Roche Truxima, a bio generic drug from TIWA and celltrion, has been approved by the US FDA at the end of November 2018 According to the terms of the agreement with Roche, truxima is expected to be listed in the US in the first half of 2019, but the details of the agreement have not been disclosed In 2018, the U.S market sales of rituximab reached $4.4 billion, almost equal to the sum of avidin and Herceptin Therefore, although the two antibody drugs may lose patents in 2019 in terms of technology, in terms of financial impact, this year's focus will be on rituximab The vagaries of biopharmaceutical development mean that low price competition for Bristol Myers Squibb autoimmune therapy orencia is unlikely to emerge soon, at least in the US market Momenta, an American biopharmaceutical company, originally cooperated with Meilan to develop a number of bio generic drugs, including orencia But at the beginning of October 2018, momenta adjusted its strategic direction, terminated the cooperation of five bio generic drugs, and only retained two drugs in the later stage (adalimumab and Aflibercept) In the U.S biosimilars market, another product that needs attention in 2019 is Anjin's heavyweight "white medicine" neulasta (peifigstein) Although the patent of this product has expired several years ago, the regulatory authorities have been delaying the listing of biosimilars until the end of 2018 Mylan and other companies hope to really open up this huge market in 2019 Tarceva is another key product for Roche to face generic competition this year Tarceva is the first representative of skin growth factor receptor (EGFR) kinase inhibitor Tarceva's position is not the same as before due to the market of the second and third generation EGFR targeted preparations Sales of the drug have continued to decline over the past four years, which may actually reduce the threat of competition as the product may be losing its appeal to generic companies Johnson & Johnson's blockbuster antipsychotic drug invega sustenna will also face generic competition in 2019, with intramuscular injection once a month However, the upgraded product invega trinza (palmitone sustained release injection, intramuscular injection once every three months) has been put on the market in 2015, which to some extent protects the sale of its franchise However, in 2019, biologics will be the field of fierce competition between original research drug manufacturers and generic drug manufacturers Many industry insiders expect that the environment of bio generic drugs in the United States will gradually start to improve, and the demand for bio generic drugs like rituximab, Herceptin and neulasta will be concerned (compiled by Sina medicine / newborn) article reference source: Roche dominantes 2019's big patent expiries